STOCK TITAN

Zai Lab Limited - ZLAB STOCK NEWS

Welcome to our dedicated news page for Zai Lab (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zai Lab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zai Lab's position in the market.

Rhea-AI Summary
Zai Lab (ZLAB) will announce its first quarter 2024 financial results and recent corporate updates on May 8, 2024. The company will host a conference call and webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) for investors and analysts to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary
Zai Lab 's executive officers commit to not selling shares until 2024, except for specific circumstances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Summary
Zai Lab to showcase Phase 1 trials of ZL-1310 and ZL-1218 at AACR 2024, highlighting innovative oncology programs targeting small cell lung cancer and solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
Rhea-AI Summary
Zai Lab and Bristol Myers Squibb announce positive results from the pivotal Phase 3 KRYSTAL-12 trial evaluating KRAZATI in KRASG12C-mutated NSCLC patients. Adagrasib shows significant benefits in progression-free survival and overall response rate compared to standard chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
Rhea-AI Summary
Zai Lab 's partner Novocure announces positive results from the phase 3 METIS clinical trial showing a significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
-
Rhea-AI Summary
Zai Lab Limited announces the presentation of preclinical data on ZL-1310, an innovative ADC targeting DLL3 for small cell lung cancer and other solid tumors at the European Lung Cancer Congress 2024. ZL-1310 shows high affinity for DLL3 and promising therapeutic potential, leading to a Phase 1 clinical trial initiation in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
Rhea-AI Summary
Zai Lab Limited to present final overall survival data from the Phase 3 NORA study on ZEJULA at 2024 ESGO and SGO conferences, showcasing the benefit of niraparib maintenance therapy for Chinese patients with platinum-sensitive recurrent ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences clinical trial
-
Rhea-AI Summary
Zai Lab Limited (ZLAB) senior management team to participate in Leerink Partners Global Biopharma Conference 2024 in Miami Beach on March 11, 2024, with a live webcast available on the company's Investor Relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited (ZLAB) reports total product revenue of $266.7 million for Full-Year 2023, showing 25% y-o-y growth. VYVGART® launch in China and inclusion on NRDL drive success. Three new potential launches expected in 2024. Financially strong with $807.6 million cash position. Strategic priorities focus on growth, profitability, and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will report financial results for the year ended December 31, 2023, and recent corporate updates on February 28, 2024. The live conference call and webcast will be held at 8:00 a.m. ET (9:00 p.m. HKT) on the same day. Listeners can access the webcast through the company's website and must register in advance. Dial-in details will be provided upon registration. A replay will be available on the website after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
Zai Lab Limited

Nasdaq:ZLAB

ZLAB Rankings

ZLAB Stock Data

1.46B
887.81M
1.83%
44.84%
3.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Shanghai

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve